OneStep ELISA Kit for Complement 1q (C1q) 
C1-q; Autoantigen Clq
Overview
Properties
- Product No.OEA747Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsEnzyme-linked immunosorbent assay for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryInfection immunityImmune moleculeAutoimmunity
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Complement 1q (C1q) and the recovery rates were calculated by comparing the measured value to the expected amount of Complement 1q (C1q) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 88-95 | 92 |
| EDTA plasma(n=5) | 92-101 | 96 |
| heparin plasma(n=5) | 91-98 | 95 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Complement 1q (C1q) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Complement 1q (C1q) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Complement 1q (C1q) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 94-102% | 85-101% | 99-105% | 78-90% |
| EDTA plasma(n=5) | 84-102% | 84-104% | 90-104% | 84-91% |
| heparin plasma(n=5) | 81-104% | 99-105% | 90-97% | 80-98% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well, then add 50µL prepared Detection Reagent A to each well. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
5. Add 50µL Stop Solution. Read at 450nm immediately.
Test principle
The test principle applied in this kit is Sandwich enzyme immunoassay. The microplate provided in this kit has been pre-coated with an antibody specific to Complement 1q (C1q). Standards or samples are then added to the appropriate microplate wells with a HRP-conjugated antibody specific to Complement 1q (C1q). After TMB substrate solution is added, only those wells that contain Complement 1q (C1q) and HRP-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Complement 1q (C1q) in the samples is then determined by comparing the O.D. of the samples to the standard curve.
Giveaways
Increment services
Citations
- Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease.PubMed: 22941511
- Characterization of complement 1q binding protein of tiger shrimp, Penaeus monodon, and its C1q binding activityPubmed: 23085472
- Acute and prolonged complement activation in the central nervous system during herpes simplex encephalitisPubmed:27235358
- The role of complement components C1q, MBL and C1 inhibitor in pathogenesis of endometriosisPubmed:29572748
- Intrathecal complement activation by the classical pathway in tick-borne encephalitisPubmed: 30850976
- Complement activation profile of patients with primary focal segmental glomerulosclerosisPubmed: 32569286
- Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary Atresia33248023
- Plasma and urine complement activation products in light chain and heavy chain deposition disease
- Matrine treatment induced an A2 astrocyte phenotype and protected the blood-brain barrier in CNS autoimmunity34280490
- Elevated Serum Complement C1q Levels After Traumatic Brain Injury and Its Association with Poor PrognosisPubmed:35035218